产品
编 号：F218238
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1801342-60-8
产品详情
生物活性：
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.
体内研究：
Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model.Animal Model:Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; five injections within 2 weeks
Result:Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.
体内研究：
Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model.Animal Model:Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; five injections within 2 weeks
Result:Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备